NCT04158258
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have newly diagnosed IV (recurrent or de novo) breast cancer no more than 12 months prior to site activation
Exclusions:
https://ClinicalTrials.gov/show/NCT04158258